VLA2001 COVID-19 vaccine clinical trials
Also written VLA2001.
How each study uses VLA2001 COVID-19 vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- VLA2001
- 6
Studies by the year they started
6 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Valneva Austria GmbH (5) · Centro de Estudios en Infectogía Pediatrica (1)
Studies
Open first, then newest update. How each study uses VLA2001 COVID-19 vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Safety and Immunogenicity of VLA2001 Adults Aged ≥56 YearsCompletedPhase 3Valneva Austria GmbHNCT04956224Written as VLA2001How we know
- VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 InfectionCompletedPhase 2/3Valneva Austria GmbHNCT05364242Written as VLA2001How we know
- COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222CompletedPhase 3Valneva Austria GmbHNCT04864561Written as VLA2001How we know
- Safety and Immunogenicity of Inactivated Heterologous Booster VaccinationWithdrawnPhase 3Centro de Estudios en Infectogía PediatricaNCT05545683Written as VLA 2001How we know
- COVID-19 Paediatric VLA2001-321 StudyWithdrawnPhase 2/3Valneva Austria GmbHNCT05298644Written as VLA2001How we know
- Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy SubjectsCompletedPhase 1/2Valneva Austria GmbHNCT04671017Written as VLA2001How we know